Quote | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
Last: | $0.0359 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0353 |
Close: | $0.0359 |
High: | $0.048 |
Low: | $0.035 |
Volume: | 10,630 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp Biofrontera launched the commercial distribution of the Rhod...
2024-05-16 14:44:07 ET Biofrontera Inc. (BFRI) Q1 2024 Earnings Conference Call May 16, 2024, 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Fina...
Message Board Posts | Biofrontera Inc. Warrants (NASDAQ:BFRIW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Biofrontera Inc. Warrants Company Name:
BFRIW Stock Symbol:
NASDAQ Market:
Biofrontera Inc. Warrants Website:
The RhodoLED XL is approved by the FDA in combination with Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp Biofrontera launched the commercial distribution of the Rhod...
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One I...
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on ...